Zacks Investment Research upgraded shares of Urogen Pharma (NASDAQ:URGN) from a hold rating to a buy rating in a research report released on Saturday morning, Zacks.com reports. The brokerage currently has $39.00 price objective on the stock.
According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “
A number of other brokerages have also weighed in on URGN. Cowen reissued a buy rating and issued a $6.50 price objective on shares of Daseke in a report on Monday, May 6th. JPMorgan Chase & Co. raised China Life Insurance from a neutral rating to an overweight rating in a report on Thursday, May 30th. They noted that the move was a valuation call. Goldman Sachs Group raised Koninklijke KPN from a neutral rating to a buy rating in a report on Wednesday, May 29th. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a buy rating in a report on Tuesday, March 19th. Finally, HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the company a buy rating in a report on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $59.00.
Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.01. Sell-side analysts anticipate that Urogen Pharma will post -5.37 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. acquired a new stake in shares of Urogen Pharma in the first quarter valued at $11,391,000. FMR LLC grew its stake in shares of Urogen Pharma by 5.8% in the first quarter. FMR LLC now owns 588,203 shares of the company’s stock valued at $21,728,000 after buying an additional 32,200 shares in the last quarter. Private Advisors LLC acquired a new stake in shares of Urogen Pharma in the first quarter valued at $329,000. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Urogen Pharma by 39.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 554,974 shares of the company’s stock valued at $20,501,000 after buying an additional 155,712 shares in the last quarter. Finally, Menora Mivtachim Holdings LTD. grew its stake in shares of Urogen Pharma by 18.2% in the first quarter. Menora Mivtachim Holdings LTD. now owns 2,954,699 shares of the company’s stock valued at $109,147,000 after buying an additional 454,829 shares in the last quarter. 97.86% of the stock is currently owned by hedge funds and other institutional investors.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Story: What is the downside to momentum investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.